Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.

Autor: Ada H V Repetto-Llamazares, Roy H Larsen, Sebastian Patzke, Karianne G Fleten, David Didierlaurent, Alexandre Pichard, Jean Pierre Pouget, Jostein Dahle

Publikováno v: PLoS ONE, Vol 10, Iss 6, p e0128816 (2015)

177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of 177Lu-HH1, 177Lu-DOTA-rituximab (177Lu-rituximab) and non-

Externí odkaz: https://doaj.org/article/16151617b83e424ea9f24337903813b1

Administration of Beta-Emitting Anti-CD37 Radioimmunoconjugate Lutetium (177Lu) Lilotomab Satetraxetan as Weekly Multiple Injections Increases Maximum Tolerated Activity in Nude Mice with Non- Hodgkin Lymphoma Xenografts

Autor: Ada H. V. Repetto-Llamazares, Jostein Dahle, Helen Heyerdahl

Publikováno v: Journal of Cancer Biology and Therapeutics. 4:181-190

Lutetium (177Lu) lilotomab satetraxetan (177Lu-lilotomab) is a novel anti-CD37 radioimmunoconjugate (RIC) currently in Phase 2b clinical trial for treatment of non-Hodgkin lymphoma (NHL). The aim of the current study was to investigate tolerability a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::237f03023a12ffc53b2b7f12212b2dff
https://doi.org/10.18314/gjct.v4i1.1091

The therapeutic effectiveness of 177Lu-lilotomab in B-cell non- Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

Autor: Alan Courteau, Julie Constanzo, Alexandre Pichard, Manuel Bardiès, Ada H. V. Repetto-Llamazares, Riad Ladjohounlou, Sara Marcatili, Jean-Pierre Pouget, Guillaume Cartron, Jihad Karam, Vilde Stenberg, Peter Coopman, Nathalie Bonnefoy, Isabelle Navarro-Teulon, Jostein Dahle, Sebastian Patzke, Helen Heyerdahl, Marta Jarlier

Publikováno v: Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2019, 34 (5), pp.1315-1328. ⟨10.1038/s41375-019-0677-4⟩
Leukemia, 2019, 34 (5), pp.1315-1328. ⟨10.1038/s41375-019-0677-4⟩

Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to rituximab (anti-CD20 antibody) therapy associated with chemotherapy. Here, the effect of the anti-CD37 antibody-radionuclide conjugate lutetium-177 (177Lu)-lilotomab (B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8fecc44caee5e5ed41191a072dc6a32
https://www.hal.inserm.fr/inserm-03024614/document

Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma

Autor: Michael Lassmann, Ada H. V. Repetto-Llamazares, Jostein Dahle, Roy H. Larsen, Camilla Mollatt

Publikováno v: Current Radiopharmaceuticals

The biodistribution of the anti-CD37 radioimmunoconjugate (177)Lu-tetraxetan-tetulomab ((177)Lu-DOTA-HH1) was evaluated. Biodistribution of (177)Lu-tetraxetan-tetulomab was compared with (177)Lu-tetraxetan-rituximab and free (177)Lu in nude mice impl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae51d67e1f626cb4f39cce6f105d9d0b
https://doi.org/10.2174/1874471011306010004

Experimental studies on shear failure of freeze-bonds in saline ice: Part I. Set-up, failure mode and freeze-bond strength

Autor: Ada H. V. Repetto-Llamazares, Karl-Ulrich Evers, Knut Vilhelm Høyland

Publikováno v: Cold Regions Science and Technology. 65:286-297

The strength of freeze-bonds in thin saline ice has been investigated through two series (in 2008 and 2009) of experiments in the Hamburg Ship Model Basin (HSVA) as a function of the normal confinement ( σ ), the submersion time (Δ t ) and the init

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f81dec4158795fa89c03868521287a0e
https://doi.org/10.1016/j.coldregions.2010.12.001